Market Cap 2.45B
Revenue (ttm) 0.00
Net Income (ttm) -154.65M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 426,600
Avg Vol 1,258,306
Day's Range N/A - N/A
Shares Out 82.50M
Stochastic %K 69%
Beta 0.49
Analysts Strong Sell
Price Target $48.50

Company Profile

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name t...

Industry: Biotechnology
Sector: Healthcare
Phone: 888 378 6240
Address:
150 N. Radnor Chester Road, Suite F200, Radnor, United States
CliffordCapital
CliffordCapital May. 12 at 8:33 PM
$MLYS give us a partner announcement
1 · Reply
ExtraRun123
ExtraRun123 May. 7 at 3:56 PM
$MLYS Interesting but too much time to PDUFA and AstraZeneca's approval might push it much lower
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 6 at 9:14 PM
$MLYS Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.47 up 40.51% YoY • Mineralys Therapeutics' NDA for lorundrostat was accepted by the FDA with a PDUFA target date of December 22, 2026, and the company's cash is sufficient to fund operations into 2028.
0 · Reply
capitalthinktank
capitalthinktank May. 5 at 1:54 PM
$MLYS is currently trading around the 30 level, where price action continues to rotate in a tight consolidation range. This area has developed into a key structural zone with prior heavy trading activity, reflecting a clear supply-demand transition. Recent volatility has contracted, indicating a compression phase ahead of potential directional expansion. Market behavior around the 30 mark is critical, as reactions here are likely to define the next structural move. Without a decisive break, price is expected to remain range-bound with rotational intraday flows, keeping the structure in a key observation phase. 👉If this helps, tap @capitalthinktank
0 · Reply
Doozio
Doozio May. 2 at 8:32 PM
Chop chop huckleberries then $GRRR s TERN to $MLYS then $BILI s ONTO 🐒🍌🧠⏰♾️
0 · Reply
CliffordCapital
CliffordCapital May. 1 at 5:28 PM
$MLYS interesting price action today… another buyout coming??
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 1 at 11:25 AM
$MLYS RSI: 50.14, MACD: -0.0701 Vol: 1.51, MA20: 28.00, MA50: 27.13 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
CliffordCapital
CliffordCapital Apr. 29 at 3:10 PM
$MLYS sorry guys. I bought in and ever since 9 straight fking red days. You can’t make this shit up 🤣🤣
1 · Reply
JBio
JBio Apr. 28 at 7:00 PM
$MLYS Undervalued. Should visit $45-$50 as we approach PDUFA. Started a position today at $26 and will add more if it visits $23
0 · Reply
Jakeipedia
Jakeipedia Apr. 28 at 6:14 PM
0 · Reply
Latest News on MLYS
Mineralys Therapeutics reports Q1 EPS (47c), consensus (44c)

2026-05-07T00:50:30.000Z - 6 days ago

Mineralys Therapeutics reports Q1 EPS (47c), consensus (44c)


Mineralys Therapeutics Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 6 days ago

Mineralys Therapeutics Earnings Call Transcript: Q1 2026


Mineralys Therapeutics initiated with a Buy at TD Cowen

2026-04-27T09:40:39.000Z - 16 days ago

Mineralys Therapeutics initiated with a Buy at TD Cowen


Mineralys Therapeutics reports Q4 EPS (40c), consensus (52c)

2026-03-12T20:36:58.000Z - 2 months ago

Mineralys Therapeutics reports Q4 EPS (40c), consensus (52c)


Mineralys Therapeutics Earnings Call Transcript: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 2 months ago

Mineralys Therapeutics Earnings Call Transcript: Q4 2025


Mineralys Therapeutics provides corporate update

2026-01-06T13:11:47.000Z - 4 months ago

Mineralys Therapeutics provides corporate update


Mineralys Therapeutics falls -11.3%

2025-11-14T17:05:26.000Z - 6 months ago

Mineralys Therapeutics falls -11.3%


Mineralys Therapeutics falls -13.9%

2025-11-14T15:06:13.000Z - 6 months ago

Mineralys Therapeutics falls -13.9%


Mineralys Therapeutics Earnings Call Transcript: Q3 2025

Nov 10, 2025, 4:30 PM EST - 6 months ago

Mineralys Therapeutics Earnings Call Transcript: Q3 2025


Mineralys Therapeutics Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 9 months ago

Mineralys Therapeutics Earnings Call Transcript: Q2 2025


Mineralys Therapeutics Transcript: Study Result

Jun 17, 2025, 8:00 AM EDT - 11 months ago

Mineralys Therapeutics Transcript: Study Result


Mineralys Therapeutics Earnings Call Transcript: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Mineralys Therapeutics Earnings Call Transcript: Q1 2025


Mineralys Therapeutics Transcript: KOL Event

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Transcript: KOL Event


Mineralys Therapeutics Transcript: Study Result

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Transcript: Study Result


Mineralys Therapeutics Earnings Call Transcript: Q4 2024

Feb 12, 2025, 8:30 AM EST - 1 year ago

Mineralys Therapeutics Earnings Call Transcript: Q4 2024


Mineralys Therapeutics Earnings Call Transcript: Q3 2024

Nov 11, 2024, 4:30 PM EST - 1 year ago

Mineralys Therapeutics Earnings Call Transcript: Q3 2024


CliffordCapital
CliffordCapital May. 12 at 8:33 PM
$MLYS give us a partner announcement
1 · Reply
ExtraRun123
ExtraRun123 May. 7 at 3:56 PM
$MLYS Interesting but too much time to PDUFA and AstraZeneca's approval might push it much lower
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 6 at 9:14 PM
$MLYS Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.47 up 40.51% YoY • Mineralys Therapeutics' NDA for lorundrostat was accepted by the FDA with a PDUFA target date of December 22, 2026, and the company's cash is sufficient to fund operations into 2028.
0 · Reply
capitalthinktank
capitalthinktank May. 5 at 1:54 PM
$MLYS is currently trading around the 30 level, where price action continues to rotate in a tight consolidation range. This area has developed into a key structural zone with prior heavy trading activity, reflecting a clear supply-demand transition. Recent volatility has contracted, indicating a compression phase ahead of potential directional expansion. Market behavior around the 30 mark is critical, as reactions here are likely to define the next structural move. Without a decisive break, price is expected to remain range-bound with rotational intraday flows, keeping the structure in a key observation phase. 👉If this helps, tap @capitalthinktank
0 · Reply
Doozio
Doozio May. 2 at 8:32 PM
Chop chop huckleberries then $GRRR s TERN to $MLYS then $BILI s ONTO 🐒🍌🧠⏰♾️
0 · Reply
CliffordCapital
CliffordCapital May. 1 at 5:28 PM
$MLYS interesting price action today… another buyout coming??
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 1 at 11:25 AM
$MLYS RSI: 50.14, MACD: -0.0701 Vol: 1.51, MA20: 28.00, MA50: 27.13 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
CliffordCapital
CliffordCapital Apr. 29 at 3:10 PM
$MLYS sorry guys. I bought in and ever since 9 straight fking red days. You can’t make this shit up 🤣🤣
1 · Reply
JBio
JBio Apr. 28 at 7:00 PM
$MLYS Undervalued. Should visit $45-$50 as we approach PDUFA. Started a position today at $26 and will add more if it visits $23
0 · Reply
Jakeipedia
Jakeipedia Apr. 28 at 6:14 PM
0 · Reply
EMINENZ
EMINENZ Apr. 27 at 4:44 PM
$MLYS 43$ before december.
1 · Reply
Quantumup
Quantumup Apr. 27 at 11:07 AM
TD Cowen🏁 $MLYS at a Buy rating. $AZN $MRK PFE TD Cowen said in its initiation report: Lorundrostat has broad, blockbuster potential in u/rHTN, a $5B+ ASI market where KOLs expect an even split among this & AZ's baxdrostat. We believe lorundro will have a better label and favorable pricing/access, and view Verona as a comp for a strong biotech launch in a pharma-dominated market where many learnings from the Q2 AZ launch can be applied and M&A should be attractive. Initiate at Buy.
0 · Reply
CliffordCapital
CliffordCapital Apr. 21 at 9:03 PM
$MLYS Check tute holdings and fillings.. blackrock loaded 35$ +.
0 · Reply
juhbubba
juhbubba Apr. 15 at 6:59 PM
0 · Reply
Src947
Src947 Apr. 15 at 5:27 PM
$MLYS today. Also put the stock on radars
0 · Reply
RonIsWrong
RonIsWrong Apr. 15 at 4:56 PM
$MLYS not sure when the rumor is from
0 · Reply
truehealthvalue
truehealthvalue Apr. 15 at 4:28 PM
$MLYS BO leaked?
1 · Reply
ap20
ap20 Apr. 15 at 3:58 PM
$MLYS Any scoop! Nice fast move…
0 · Reply
crazysnake
crazysnake Apr. 6 at 4:00 PM
$MLYS probably already a buyout deal for mineralys 100% institutional ownership up 4% today take a look $OCGN $TNXP $SLS
1 · Reply
dgbio
dgbio Apr. 6 at 3:50 PM
$MLYS The second board appointment in a week for Congleton. He is busy building his future after Mineralys. https://www.globenewswire.com/news-release/2026/04/06/3268393/0/en/Avalyn-Appoints-Jon-Congleton-Seasoned-Biopharmaceutical-Executive-to-its-Board-of-Directors.html
0 · Reply
crazysnake
crazysnake Apr. 2 at 7:22 PM
$OCGN ocugen and mineralys $MLYS my two biggest positions
0 · Reply
Jakeipedia
Jakeipedia Mar. 31 at 6:48 PM
$MLYS this is fun
0 · Reply